Updates in Treatment of Refractory Inflammatory Myositis
Canadian Rheumatology Today · 2024
DOI: 10.58931/crt.2024.1145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Rheumatology Today, 2024. Verfasst von Kun Huang und 1 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Idiopathic immune myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune diseases with varying phenotypes, prognoses, and treatment responses. They are primarily characterized by muscle inflammation, however, many patients have extramuscular involvement including skin rash, arthritis, interstitial lung disease (ILD), cardiomyopathy, and gastrointestinal dysmotility. The discovery of myositis-specific autoantibodies (MSAs) has been a major advancement in the field of IIMs, shaping the new landscape of the clinical, phenotypical, histological, and serological correlations. Based on this discovery, IIM can be more specifically classified into dermatomyositis (DM) (including amyopathic DM), antisynthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), polymyositis (PM), and overlap myositis (OM). An increasing number of histological studies have revealed a misdiagnosis of PM because many patients who were previously diagnosed with PM were later reclassified to other forms of IIM, including IBM, IMNM, ASyS, or DM without a rash.
Zitieren
APA
Huang, K., & Pye, A. (2024). Updates in Treatment of Refractory Inflammatory Myositis. Canadian Rheumatology Today. https://doi.org/10.58931/crt.2024.1145
Vancouver
Huang K, Pye A. Updates in Treatment of Refractory Inflammatory Myositis. Canadian Rheumatology Today. 2024. doi:10.58931/crt.2024.1145
BibTeX
@article{Huang2024,
author = {Huang, Kun and Pye, Aidan},
title = {Updates in Treatment of Refractory Inflammatory Myositis},
journal = {Canadian Rheumatology Today},
year = {2024},
doi = {10.58931/crt.2024.1145}
}
EUVIMED